Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Learn which credit cards offer no annual fee along with bonus rewards. Make an informed choice for your finances!
28,655 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A security flaw allowed a hacker to drain approximately $5.9 million from TrustedVolumes, a DeFi liquidity provider o...
NVIDIA hits fresh highs after U.S. regulators approve more H200 chip sales to China, lifting momentum across the AI c...
In a move that stirs controversy, a $1.7 billion fund is being created to compensate allies in a settlement tied to T...
A stock can drop today for many reasons—some temporary, some signaling a bigger issue. This guide shows you how to ev...
A seven-name AI hardware rally is reshaping bets for 2026, with Parabolic 7 outpacing the Magnificent 7 and drawing n...
NVIDIA CEO Jensen Huang positioned the latest AI stock pullback as a buying opportunity, a stance that reminds invest...
As AI workloads spur hyperscale data-center expansion, Vertiv’s order book signals a durable cycle that could lift th...
Civilians in the Black Sea peninsula face fuel shortages as russia-occupied crimea halts gas sales amid intensified U...
Taiko’s Ethereum Layer 2 network has confirmed a breach in its chain state verification, prompting an urgent call for...
Institutional funds are piling into crypto stocks as a regulated way to gain exposure to digital assets. The question...
When a chief operating officer sells stock, investors take notice. This article breaks down the implications, explain...